Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
MERMAID-2
Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.
- NCT04642469 ↗
- Completed
- AstraZeneca
- Focused
We haven't built an HCP commentary report on MERMAID-2 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on MERMAID-2 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients With Minimal Residual Disease Following Surgery and Curative Intent Therapy.
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Carcinoma, Non- Small Cell Lung
- Interventions
- Durvalumab; Placebo
- Arms
- Durvalumab · Experimental
- Placebo · Placebo comparator
- Enrollment
- 30
- Primary outcomes
- Disease-free Survival (DFS)
- Sponsor
- AstraZeneca
- Start
- Nov 30, 2020
- Primary completion
- May 31, 2023
- Results posted
- Yes
- Registry record
- NCT04642469 · updated Jun 25, 2024